This inventor holds 2 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignee: Bristol-Myers Squibb Compnay. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Umesh Kestur: Innovator in Pharmaceutical Formulations
Introduction
Umesh Kestur is a notable inventor based in North Brunswick, NJ (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative dosage forms for Tyk2 inhibitors. His work is crucial for advancing treatments for various auto-immune and auto-inflammatory diseases.
Latest Patents
Umesh Kestur holds a patent for "Dosage forms for Tyk2 inhibitors." This patent describes stable and bioavailable formulations and dosage forms that comprise a dispersion of solid amorphous 6-(cyclopropancamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (Formula (I): BMS-986165). These formulations are designed for the treatment of auto-immune and auto-inflammatory diseases, including inflammatory bowel disease (IBD) and psoriasis. Umesh Kestur has 1 patent to his name.
Career Highlights
Umesh Kestur is currently employed at Bristol-Myers Squibb Company, where he continues to innovate in the pharmaceutical sector. His work focuses on creating effective and stable drug formulations that can improve patient outcomes.
Collaborations
Umesh has collaborated with several talented individuals in his field, including Sherif Ibrahim Farag Badawy and Jonathan R Brown. These collaborations have contributed to the advancement of his research and the successful development of his patented formulations.
Conclusion
Umesh Kestur is a dedicated inventor whose work in pharmaceutical formulations is making a significant impact on the treatment of auto-immune diseases. His innovative approach and collaboration with other experts highlight the importance of teamwork in scientific advancements.